

Novel methods to improve detection and outcomes of prostate cancer

Poster Session 26

Saturday, 25 March
16:00 - 17:30

Location: Room Stockholm, North Hall (Level 1)

Chairs: A. Rannikko, Helsinki (FI)
P. Stattin, Uppsala (SE)
L-P. Xie, Hangzhou (CN)

Aims and objectives of this session

The aim of this session is to provide an update on novel approach to improve detection and outcomes of prostate cancer.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- 344 **Repeat prostate-specific antigen tests before prostate biopsy: A decreasing in PSA values is associated with a reduced risk of cancer and particularly high grade cancer**
By: De Nunzio C., Lombardo R., Presicce F., Deroma M., Tema G., Cancrini F., Tubaro A.
Institutes:Sant' Andrea Hospital - Sapienza University, Dept. of Urology, Rome, Italy
- 345 **Atorvastatin before prostatectomy and prostate cancer - a randomized, double-blind, placebo controlled clinical trial**
By: Murtola T.¹, Riikonen J.¹, Syväälä H.², Tolonen T.³, Koskimäki J.¹, Pakarainen T.¹, Kaipia A.⁴, Isotalo T.⁵, Kujala P.³, Tammela T.¹
Institutes:¹Tampere University Hospital, Dept. of Urology, Tampere, Finland, ²University of Tampere, School of Medicine, Tampere, Finland, ³Fimlab Laboratories, Dept. of Pathology, Tampere, Finland, ⁴Satakunta Central Hospital, Dept. of Urology, Pori, Finland, ⁵Päijät-Häme Central Hospital, Dept. of Urology, Lahti, Finland
- 346 **The effect of metformin use and the incidence of prostate cancer in type 2 diabetes mellitus patients: A nationwide population-based study**
By: Yun S.J.¹, Kim S.Y.², Park J-H.³, Cho I-C.⁴, Jeong P.⁵, Kang H.W.⁵, Ha Y-S.⁶, Kim W.T.⁵, Kim Y-J.⁵, Lee S.C.⁵, Kim W-J.⁵
Institutes:¹Chungbuk National University, Dept. of Urology, Cheongju, South Korea, ²Chungbuk National University Hospital, Office of Public Health, Cheongju, South Korea, ³College of Medicine, Chungbuk National University, Dept. of Preventive Medicine, Cheongju, South Korea, ⁴National Police Hospital, Dept. of Urology, Seoul, South Korea, ⁵Chungbuk National University College of Medicine, Dept. of Urology, Cheongju, South Korea, ⁶Kyungpook National University Medical Center, Dept. of Urology, Daegu, South Korea
- 347 **An automated-microcapillary electrophoresis-based immunoassay system may improve diagnostic accuracy of prostate cancer and be a good indicator of biopsy Gleason score**
By: Ishikawa T.¹, Yoneyama T.¹, Tobisawa Y.¹, Hatakeyama S.¹, Kurosawa T.², Nakamura K.², Koie T.¹, Hashimoto Y.¹, Ohyama C.¹
Institutes:¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Wako Pure Chemical Industries, Ltd., Diagnostics Research Laboratories, Amagasaki, Japan
- 348 **Association between single nucleotide polymorphisms, gene expression and prostate cancer risk at the moment of diagnosis**
By: Puche Sanz I.¹, Robles-Fernández I.², Pascual-Geler M.¹, Martínez-Gonzalez L.², Lorente J.A.², Cózar-Olmo J.M.¹, Álvarez-Cubero M.J.²
Institutes:¹Complejo Hospitalario Universitario Granada, Dept. of Urology, Granada, Spain, ²Pfizer-

University of Granada-Junta De Andalucía Centre For Genomics and Oncological Research (GENYO), Dept. of Genomics, Granada, Spain

- 349 **Clinical usefulness of eight novel monoclonal antibodies against prostate-specific antigen (PSA) to differentiate prostate cancer and benign prostate hyperplasia. Measurement of different PSA molecular forms with specific immunoassays**
By: Navarro S.², Royo M.², Martos L.², Vera Donoso C.D.¹, Martinez-Sarmiento M.¹, Alapont J.M.¹, Ramon L.A.², Oto J.², España F.², Medina-Badenes P.²
Institutes:¹La Fe, University and Polytechnic Hospital, Dept. of Urology, Valencia, Spain, ²Instituto De Investigación Sanitaria La Fe, Grupo De Hemostasia, Trombosis, Arteriosclerosis Y Biología Vasculard, Valencia, Spain
- 350 **Defining a cohort of men who may not require repeat prostate biopsy based on PCA3 and MRI: The double negative effect**
By: Perlis N.¹, Al-Kasab T.¹, Ahmad A.¹, Goldberg E.¹, Fadak K.¹, Sayyid R.¹, Finelli A.¹, Kulkarni G.¹, Hamilton R.¹, Zlotta A.², Fleshner N.¹
Institutes:¹University of Toronto, University Health Network, Dept. of Surgical Oncology, Division of Urology, Toronto, Canada, ²University of Toronto, University Health Network and Sinai Health System, Dept. of Surgical Oncology, Division of Urology, Toronto, Canada
- 351 **Circulating tumor cells as a marker of bone metastases in patients with high-risk prostate cancer**
By: Cieřlikowski W.A.¹, Ida A.¹, Hrab M.¹, Budna J.², ĩwierczewska M.², Jankowiak A.², Zabel M.², Antczak A.¹
Institutes:¹Poznań University of Medical Sciences, Dept. of Urology, Poznań, Poland, ²Poznań University of Medical Sciences, Dept. of Histology and Embryology, Poznań, Poland
- 352 **Clinical validation of a 17-gene genomic prostate score (GPS) assay as a predictor of distant metastases in men with prostate cancer (PCa) treated with radical prostatectomy (RP) in a community setting**
By: Van Den Eeden S.¹, Zhang N.⁴, Shan J.¹, Quesenberry C.¹, Han J.², Tsiatis A.³, Lu R.⁴, Lawrence J.⁵, Febbo P.⁵, Presti J.⁶
Institutes:¹Kaiser Permanente Northern California, Dept. of Research, Oakland, United States of America, ²Kaiser Oakland Medical Center, Dept. of Pathology, Oakland, United States of America, ³Genomic Health, Dept. of Pathology, Redwood City, United States of America, ⁴Genomic Health, Dept. of Biostatistics, Redwood City, United States of America, ⁵Genomic Health, Medical Department, Redwood City, United States of America, ⁶Kaiser Oakland Medical Center, Dept. of Urology, Oakland, United States of America
- 353 **Serum miRNA-supported transrectal MRI-ultrasound fusion-guided biopsy of the prostate enhances tumor prediction and classification**
By: Keck B., Wach S., Pöllmann J., Jansen T., Kahlmeyer A., Taubert H., Wullich B.
Institutes:University Hospital Erlangen, Dept. of Urology, Erlangen, Germany
- 354 **The influence of physical activity on prostate cancer diagnosis: A multicenter biopsy cohort analysis**
By: De Nunzio C.¹, Cindolo L.², Sountoulidis P.³, Toutziaris C.⁴, Gacci M.⁵, Presicce F.¹, Cancrini F.¹, Schips L.², Serni S.⁵, Tubaro A.¹
Institutes:¹Sant'Andrea Hospital - Sapienza University, Dept. of Urology, Rome, Italy, ²Padre Pio Da Pietrelcina Hospital, Dept. of Urology, Vasto, Italy, ³General Hospital of Veria, Dept. of Urology, Veria, Greece, ⁴Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece, ⁵Careggi Hospital, Dept. of Urology, Florence, Italy
- 355 **Mutation of duffy antigen receptor for chemokines (DARC) as an indicator of prostate cancer severity in Afro-Caribbean men**
By: Galustian C.¹, Rani A.¹, Cahill F.², Santaolalla A.², Gillett C.³, Lombardelli C.³, Rosekilly J.³, Sakellariou C.¹, George G.², Papaevangelou E.¹, Smith R.⁴, Smolarek D.⁴, Van Hemelrijck M.², Dasgupta P.⁴
Institutes:¹Kings College London, Innate Immunity, MRC Centre for Transplantation, London,

United Kingdom, ²Kings College London, Cancer Epidemiology Group, Division of Cancer Sciences, London, United Kingdom, ³Kings College London, KHP Cancer Biobank, 3rd Floor Bermondsey Wing Guy's Hospital, London, United Kingdom, ⁴Kings College London, MRC Centre for Transplantation, and Urology Centre, London, United Kingdom

*356

Germline mutations in the Kallikrein 6 region and predisposition for aggressive prostate cancer

By: Briollais L.², Ozcelik H.², Xu J.², Kwiatkowski M.³, Lalonde E.⁴, Sendorek D.⁴, Fleshner N.⁵, Recker F.³, Kuk C.⁶, Olkhov-Mitsel E.², Savas S.⁷, Hanna S.⁸, Juvet T.⁵, Hunter G.⁴, Friedlander M.², Li H.², Chadwick K.⁵, Prassas I.⁹, Soosaipillai A.⁹, Randazzo M.³, Trachtenberg J.⁵, Toi A.⁵, Shiah Y-J.⁴, Fraser M.¹⁰, Van Der Kwast T.¹¹, Bristow R.¹⁰, Bapat B.², Diamandis E.⁹, Boutros P.⁴, Zlotta A.¹

Institutes: ¹Mount Sinai Hospital, Dept. of Surgery (urology), Toronto, Canada, ²Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada, ³Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland, ⁴Ontario Institute For Cancer Research, Informatics & Biocomputing Program, Toronto, Canada, ⁵Princess Margaret Hospital, University Health Network, Dept. of Surgical Oncology, Urology, Toronto, Canada, ⁶Mount Sinai Hospital, Dept. of Surgery and Urology, Toronto, Canada, ⁷Memorial University, Craig L. Dobbin Genetics Research Centre, Discipline of Genetics, Faculty of Medicine, St. John's, Canada, ⁸Mount Sinai Hospital, Dept. of Surgery, Urology, Toronto, Canada, ⁹Mount Sinai Hospital, Dept. of Pathology and Laboratory Medicine, Toronto, Canada, ¹⁰Princess Margaret Hospital, University Health Network, Ontario Cancer Institute, Toronto, Canada, ¹¹Toronto General Hospital, University Health Network, Dept. of Pathology, Toronto, Canada

17:17 - 17:24

Summary

A. Rannikko, Helsinki (FI)